首页 > 最新文献

Bladder Cancer最新文献

英文 中文
A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Resection. 经尿道切除术后辅助预防性治疗的非肌层浸润性膀胱癌疗效试验中结果报告、定义和测量异质性的系统性回顾。
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2021-05-25 eCollection Date: 2021-01-01 DOI: 10.3233/BLC-201510
Erik Veskimae, Selvarani Subbarayan, Riccardo Campi, Domitille Carron, Muhammad Imran Omar, Cathy Yuan, Konstantinos Dimitropoulos, Mieke Van Hemelrijck, Richard T Bryan, James N'Dow, Marek Babjuk, J Alfred Witjes, Richard Sylvester, Steven MacLennan

Background: Heterogenous outcome reporting in non-muscle-invasive bladder cancer (NMIBC) effectiveness trials of adjuvant treatment after transurethral resection (TURBT) has been noted in systematic reviews (SRs). This hinders comparing results across trials, combining them in meta-analyses, and evidence-based decision-making for patients and clinicians.

Objective: We aimed to systematically review the extent of reporting and definition heterogeneity.

Methods: We included randomized controlled trials (RCTs) identified from SRs comparing adjuvant treatments after TURBT or TURBT alone in patients with NMIBC (with or without carcinoma in situ) published between 2000-2020. Abstracts and full texts were screened independently by two reviewers. Data were extracted by one reviewer and checked by another.

Results: We screened 807 abstracts; from 15 SRs, 57 RCTs were included. Verbatim outcome names were coded to standard outcome names and organised using the Williamson and Clarke taxonomy. Recurrence (98%), progression (74%), treatment response (in CIS studies) (40%), and adverse events (77%) were frequently reported across studies. However, overall (33%) and cancer-specific (33%) survival, treatment completion (17%) and treatment change (37%) were less often reported. Quality of Life (3%) and economic outcomes (2%) were rarely reported. Heterogeneity was evident throughout, particularly in the definitions of progression and recurrence, and how CIS patients were handled in the analysis of studies with predominantly papillary patients, highlighting further issues with the definition of recurrence and progression vs treatment response for CIS patients. Data reporting was also inconsistent, with some trials reporting event rates at various time-points and others reporting time-to-event with or without Hazard Ratios. Adverse events were inconsistently reported. QoL data was absent in most trials.

Conclusions: Heterogenous outcome reporting is evident in NMIBC effectiveness trials. This has profound implications for meta-analyses, SRs and evidence-based treatment decisions. A core outcome set is required to reduce heterogeneity.

Patient summary: This systematic review found inconsistencies in outcome definitions and reporting, pointing out the urgent need for a core outcome set to help improve evidence-based treatment decisions.

背景:经尿道膀胱切除术(TURBT)后辅助治疗的非肌层浸润性膀胱癌(NMIBC)有效性试验中的结果报告不尽相同,这在系统综述(SR)中已被注意到。这阻碍了对不同试验结果的比较、将其纳入荟萃分析以及患者和临床医生的循证决策:目的:我们旨在系统回顾报告和定义异质性的程度:我们纳入了 2000-2020 年间发表的随机对照试验 (RCT),这些试验是从 SR 中确定的,比较了 NMIBC(有或无原位癌)患者 TURBT 或 TURBT 后的辅助治疗。摘要和全文由两名审稿人独立筛选。数据由一位审稿人提取,另一位审稿人核对:我们筛选了 807 篇摘要;从 15 篇研究报告中纳入了 57 篇 RCT。逐字记录的结果名称被编码为标准结果名称,并使用威廉姆森和克拉克分类法进行整理。复发(98%)、病情进展(74%)、治疗反应(在 CIS 研究中)(40%)和不良事件(77%)是各研究中经常报告的内容。然而,总体生存率(33%)和癌症特异性生存率(33%)、治疗完成率(17%)和治疗改变率(37%)的报告较少。生活质量(3%)和经济结果(2%)很少被报道。异质性在所有研究中都很明显,特别是在进展和复发的定义方面,以及在对主要为乳头状患者的研究进行分析时如何处理CIS患者,这进一步突出了CIS患者复发和进展与治疗反应的定义问题。数据报告也不一致,一些试验报告了不同时间点的事件发生率,另一些试验则报告了有或无危险比的事件发生时间。不良事件的报告也不一致。大多数试验缺乏 QoL 数据:结论:在 NMIBC 疗效试验中,结果报告的不一致性非常明显。这对荟萃分析、SR 和循证治疗决策具有深远影响。患者总结:本系统综述发现了结果定义和报告的不一致性,指出迫切需要一套核心结果集来帮助改善循证治疗决策。
{"title":"A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Resection.","authors":"Erik Veskimae, Selvarani Subbarayan, Riccardo Campi, Domitille Carron, Muhammad Imran Omar, Cathy Yuan, Konstantinos Dimitropoulos, Mieke Van Hemelrijck, Richard T Bryan, James N'Dow, Marek Babjuk, J Alfred Witjes, Richard Sylvester, Steven MacLennan","doi":"10.3233/BLC-201510","DOIUrl":"10.3233/BLC-201510","url":null,"abstract":"<p><strong>Background: </strong>Heterogenous outcome reporting in non-muscle-invasive bladder cancer (NMIBC) effectiveness trials of adjuvant treatment after transurethral resection (TURBT) has been noted in systematic reviews (SRs). This hinders comparing results across trials, combining them in meta-analyses, and evidence-based decision-making for patients and clinicians.</p><p><strong>Objective: </strong>We aimed to systematically review the extent of reporting and definition heterogeneity.</p><p><strong>Methods: </strong>We included randomized controlled trials (RCTs) identified from SRs comparing adjuvant treatments after TURBT or TURBT alone in patients with NMIBC (with or without carcinoma <i>in situ</i>) published between 2000-2020. Abstracts and full texts were screened independently by two reviewers. Data were extracted by one reviewer and checked by another.</p><p><strong>Results: </strong>We screened 807 abstracts; from 15 SRs, 57 RCTs were included. Verbatim outcome names were coded to standard outcome names and organised using the Williamson and Clarke taxonomy. Recurrence (98%), progression (74%), treatment response (in CIS studies) (40%), and adverse events (77%) were frequently reported across studies. However, overall (33%) and cancer-specific (33%) survival, treatment completion (17%) and treatment change (37%) were less often reported. Quality of Life (3%) and economic outcomes (2%) were rarely reported. Heterogeneity was evident throughout, particularly in the definitions of progression and recurrence, and how CIS patients were handled in the analysis of studies with predominantly papillary patients, highlighting further issues with the definition of recurrence and progression vs treatment response for CIS patients. Data reporting was also inconsistent, with some trials reporting event rates at various time-points and others reporting time-to-event with or without Hazard Ratios. Adverse events were inconsistently reported. QoL data was absent in most trials.</p><p><strong>Conclusions: </strong>Heterogenous outcome reporting is evident in NMIBC effectiveness trials. This has profound implications for meta-analyses, SRs and evidence-based treatment decisions. A core outcome set is required to reduce heterogeneity.</p><p><strong>Patient summary: </strong>This systematic review found inconsistencies in outcome definitions and reporting, pointing out the urgent need for a core outcome set to help improve evidence-based treatment decisions.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"7 2","pages":"221-241"},"PeriodicalIF":1.0,"publicationDate":"2021-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Trials Corner Issue 7(2). 临床试验角》第 7(2)期。
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2021-05-25 eCollection Date: 2021-01-01 DOI: 10.3233/BLC-200018
Piyush K Agarwal, Cora N Sternberg
{"title":"Clinical Trials Corner Issue 7(2).","authors":"Piyush K Agarwal, Cora N Sternberg","doi":"10.3233/BLC-200018","DOIUrl":"10.3233/BLC-200018","url":null,"abstract":"","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"7 2","pages":"257-260"},"PeriodicalIF":1.0,"publicationDate":"2021-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Outcomes of Trimodal Therapy for cT2-3 Urothelial Carcinoma in a Racially Diverse Population: A Single Institution Experience in the Bronx. 勘误:三联疗法在不同种族人群中治疗 cT2-3 尿路上皮癌的效果:布朗克斯区一家医疗机构的经验。
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2021-03-19 DOI: 10.3233/BLC-219501

[This corrects the article DOI: 10.3233/BLC-200332.].

[此处更正了文章 DOI:10.3233/BLC-200332]。
{"title":"Erratum: Outcomes of Trimodal Therapy for cT2-3 Urothelial Carcinoma in a Racially Diverse Population: A Single Institution Experience in the Bronx.","authors":"","doi":"10.3233/BLC-219501","DOIUrl":"10.3233/BLC-219501","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3233/BLC-200332.].</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"7 1","pages":"111-112"},"PeriodicalIF":1.0,"publicationDate":"2021-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/45/blc-7-blc219501.PMC8080894.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38908688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Challenging Cases in Urothelial Cancer. 勘误:泌尿道癌的疑难病例。
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2021-03-19 eCollection Date: 2021-01-01 DOI: 10.3233/BLC-219602
Mark S Soloway, Neil A Abrahams

[This corrects the article DOI: 10.3233/BLC-200004.].

[此处更正了文章 DOI:10.3233/BLC-200004]。
{"title":"Erratum: Challenging Cases in Urothelial Cancer.","authors":"Mark S Soloway, Neil A Abrahams","doi":"10.3233/BLC-219602","DOIUrl":"https://doi.org/10.3233/BLC-219602","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3233/BLC-200004.].</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"7 1","pages":"115"},"PeriodicalIF":1.0,"publicationDate":"2021-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11185922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer. 勘误:晚期膀胱癌患者对 PD-1/ PD-L1 免疫检查点阻断剂反应的分子生物标记物
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2021-03-19 DOI: 10.3233/BLC-219500

[This corrects the article DOI: 10.3233/BLC-200013.].

[此处更正了文章 DOI:10.3233/BLC-200013]。
{"title":"Erratum: Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer.","authors":"","doi":"10.3233/BLC-219500","DOIUrl":"10.3233/BLC-219500","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3233/BLC-200013.].</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"7 1","pages":"109"},"PeriodicalIF":1.0,"publicationDate":"2021-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/3a/blc-7-blc219500.PMC8080893.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38908687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bladder Cancer Health Literacy: Assessing Readability of Online Patient Education Materials. 膀胱癌健康扫盲:评估在线患者教育材料的可读性。
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2021-03-19 eCollection Date: 2021-01-01 DOI: 10.3233/BLC-200387
Lauren E Powell, Theodore I Cisu, Adam P Klausner

Background: Understanding of health-related materials, termed health literacy, affects decision makings and outcomes in the treatment of bladder cancer. The National Institutes of Health recommend writing education materials at a sixth-seventh grade reading level. The goal of this study is to assess readability of bladder cancer materials available online.

Objective: The goal of this study is to characterize available information about bladder cancer online and evaluate readability.

Methods: Materials on bladder cancer were collected from the American Urological Association's Urology Care Foundation (AUA-UCF) and compared to top 50 websites by search engine results. Resources were analyzed using four different validated readability assessment scales. The mean and standard deviation of the materials was calculated, and a two-tailed t test for used to assess for significance between the two sets of patient education materials.

Results: The average readability of AUA materials was 8.5 (8th-9th grade reading level). For the top 50 websites, average readability was 11.7 (11-12th grade reading level). A two-tailed t test between the AUA and top 50 websites demonstrated statistical significance between the readability of the two sets of resources (P = 0.0001), with the top search engine results being several grade levels higher than the recommended 6-7th grade reading level.

Conclusions: Most health information provided by the AUA on bladder cancer is written at a reading ability that aligns with most US adults, with top websites for search engine results exceeding the average reading level by several grade levels. By focusing on health literacy, urologists may contribute lowering barriers to health literacy, improving health care expenditure and perioperative complications.

背景:对健康相关材料的理解(即健康素养)会影响治疗膀胱癌的决策和结果。美国国立卫生研究院建议按照六至七年级的阅读水平编写教材。本研究旨在评估网上膀胱癌资料的可读性:本研究的目的是了解网上现有膀胱癌信息的特点并评估其可读性:方法:从美国泌尿外科协会泌尿外科护理基金会(AUA-UCF)收集有关膀胱癌的资料,并与搜索引擎结果排名前 50 位的网站进行比较。使用四种不同的经过验证的可读性评估量表对资源进行了分析。计算了材料的平均值和标准偏差,并使用双尾t检验来评估两套患者教育材料之间的显著性:结果:友盟材料的平均可读性为 8.5(8-9 年级阅读水平)。排名前 50 的网站的平均可读性为 11.7(11-12 年级阅读水平)。对美国友协和排名前 50 的网站进行的双尾 t 检验表明,两组资源的可读性之间存在统计学意义(P = 0.0001),排名靠前的搜索引擎结果比建议的 6-7 年级阅读水平高出几个年级:结论:美国膀胱癌协会提供的大多数膀胱癌健康信息的阅读能力与大多数美国成年人的阅读能力相符,搜索引擎结果中排名靠前的网站比平均阅读水平高出几个年级。通过关注健康素养,泌尿科医生可以为降低健康素养障碍、改善医疗支出和围手术期并发症做出贡献。
{"title":"Bladder Cancer Health Literacy: Assessing Readability of Online Patient Education Materials.","authors":"Lauren E Powell, Theodore I Cisu, Adam P Klausner","doi":"10.3233/BLC-200387","DOIUrl":"10.3233/BLC-200387","url":null,"abstract":"<p><strong>Background: </strong>Understanding of health-related materials, termed health literacy, affects decision makings and outcomes in the treatment of bladder cancer. The National Institutes of Health recommend writing education materials at a sixth-seventh grade reading level. The goal of this study is to assess readability of bladder cancer materials available online.</p><p><strong>Objective: </strong>The goal of this study is to characterize available information about bladder cancer online and evaluate readability.</p><p><strong>Methods: </strong>Materials on bladder cancer were collected from the American Urological Association's Urology Care Foundation (AUA-UCF) and compared to top 50 websites by search engine results. Resources were analyzed using four different validated readability assessment scales. The mean and standard deviation of the materials was calculated, and a two-tailed <i>t</i> test for used to assess for significance between the two sets of patient education materials.</p><p><strong>Results: </strong>The average readability of AUA materials was 8.5 (8th-9th grade reading level). For the top 50 websites, average readability was 11.7 (11-12th grade reading level). A two-tailed <i>t</i> test between the AUA and top 50 websites demonstrated statistical significance between the readability of the two sets of resources (<i>P</i> = 0.0001), with the top search engine results being several grade levels higher than the recommended 6-7th grade reading level.</p><p><strong>Conclusions: </strong>Most health information provided by the AUA on bladder cancer is written at a reading ability that aligns with most US adults, with top websites for search engine results exceeding the average reading level by several grade levels. By focusing on health literacy, urologists may contribute lowering barriers to health literacy, improving health care expenditure and perioperative complications.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"7 1","pages":"91-98"},"PeriodicalIF":1.0,"publicationDate":"2021-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Challenging Cases in Urothelial Cancer: Case 17. 勘误:泌尿道癌的疑难病例:病例 17.
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2021-03-19 eCollection Date: 2021-01-01 DOI: 10.3233/BLC-219603
Mark S Soloway

[This corrects the article DOI: 10.3233/BLC-200007.].

[此处更正了文章 DOI:10.3233/BLC-200007.]。
{"title":"Erratum: Challenging Cases in Urothelial Cancer: Case 17.","authors":"Mark S Soloway","doi":"10.3233/BLC-219603","DOIUrl":"https://doi.org/10.3233/BLC-219603","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3233/BLC-200007.].</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"7 1","pages":"117"},"PeriodicalIF":1.0,"publicationDate":"2021-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11185921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Challenging Cases in Urothelial Cancer. 勘误:泌尿道癌的疑难病例。
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2021-03-19 eCollection Date: 2021-01-01 DOI: 10.3233/BLC-219601
Mark S Soloway

[This corrects the article DOI: 10.3233/BLC-200001.].

[此处更正了文章 DOI:10.3233/BLC-200001]。
{"title":"Erratum: Challenging Cases in Urothelial Cancer.","authors":"Mark S Soloway","doi":"10.3233/BLC-219601","DOIUrl":"https://doi.org/10.3233/BLC-219601","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3233/BLC-200001.].</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"7 1","pages":"113"},"PeriodicalIF":1.0,"publicationDate":"2021-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11185919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenging Cases in Urothelial Cancer: Case 19. 泌尿道癌的挑战性病例:病例 19.
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2021-03-19 eCollection Date: 2021-01-01 DOI: 10.3233/BLC-200015
Mark S Soloway, Neil A Abrahams
{"title":"Challenging Cases in Urothelial Cancer: Case 19.","authors":"Mark S Soloway, Neil A Abrahams","doi":"10.3233/BLC-200015","DOIUrl":"10.3233/BLC-200015","url":null,"abstract":"","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"1 1","pages":"99-102"},"PeriodicalIF":1.0,"publicationDate":"2021-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69809167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Challenging Cases in Urothelial Cancer: Case 18. 勘误:尿道癌的疑难病例:病例 18.
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2021-03-19 eCollection Date: 2021-01-01 DOI: 10.3233/BLC-219604
Mark S Soloway

[This corrects the article DOI: 10.3233/BLC-200009.].

[此处更正了文章 DOI:10.3233/BLC-200009]。
{"title":"Erratum: Challenging Cases in Urothelial Cancer: Case 18.","authors":"Mark S Soloway","doi":"10.3233/BLC-219604","DOIUrl":"https://doi.org/10.3233/BLC-219604","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3233/BLC-200009.].</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"7 1","pages":"119"},"PeriodicalIF":1.0,"publicationDate":"2021-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11185920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Bladder Cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1